Data Sheet (Cat.No.T3836)

TargetMol

Eudesmin

Chemical Properties



CAS No. : 526-06-7

Formula: C22H26O6

Molecular Weight: 386.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Eudesmin shows antiinflammatory, neuritogenic, anticonvulsant and sedative effects, the mechanism of eudesmin may be related to up-regulation of GABAA and GAD65 expressions, and anti-apoptosis of neuron the in brain.50 microM (+)-eudesmin can induce neurite outgrowth and enhance nerve growth factor (NGF)-mediated neurite outgrowth from PC12 cells by stimulating up-stream MAPK, PKC and PKA pathways.
Targets(IC50)	MAPK,S6 Kinase

Solubility Information

Solubility	DMSO: 25 mg/mL (64.69 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.18 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5877 mL	12.9386 mL	25.8772 mL
5 mM	0.5175 mL	2.5877 mL	5.1754 mL
10 mM	0.2588 mL	1.2939 mL	2.5877 mL
50 mM	0.0518 mL	0.2588 mL	0.5175 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cho J Y , Yoo E S , Baik K U , et al. Eudesmin inhibits tumor necrosis factor-alpha production and T cell proliferation [J]. Archives of Pharmacal Research, 1999, 22(4):348-353.
Yang C, Xu H, Yang D, et al.A renal YY1-KIM1-DR5 axis regulates the progression of acute kidney injury.Nature Communications.2023, 14(1): 4261.